NO20042902L - Krystallinsk atorvastatinkalsium pa form Je, fremgangsmater for fremstilling derav, et farmasoytisk preparat omfattende denne samt dens anvendelse - Google Patents
Krystallinsk atorvastatinkalsium pa form Je, fremgangsmater for fremstilling derav, et farmasoytisk preparat omfattende denne samt dens anvendelseInfo
- Publication number
- NO20042902L NO20042902L NO20042902A NO20042902A NO20042902L NO 20042902 L NO20042902 L NO 20042902L NO 20042902 A NO20042902 A NO 20042902A NO 20042902 A NO20042902 A NO 20042902A NO 20042902 L NO20042902 L NO 20042902L
- Authority
- NO
- Norway
- Prior art keywords
- processes
- preparation
- pharmaceutical composition
- atorvastatin calcium
- crystalline atorvastatin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
- C07D207/327—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/337—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34113301P | 2001-12-12 | 2001-12-12 | |
| PCT/US2002/039512 WO2003050085A1 (en) | 2001-12-12 | 2002-12-11 | CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-β,δ-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-HEPTANOIC ACID CALCIUM SALT (2:1) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20042902L true NO20042902L (no) | 2004-09-09 |
Family
ID=23336363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20042902A NO20042902L (no) | 2001-12-12 | 2004-07-09 | Krystallinsk atorvastatinkalsium pa form Je, fremgangsmater for fremstilling derav, et farmasoytisk preparat omfattende denne samt dens anvendelse |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20050209306A1 (ru) |
| EP (1) | EP1472220A4 (ru) |
| JP (1) | JP2005516008A (ru) |
| KR (1) | KR20040091612A (ru) |
| CN (2) | CN101565394A (ru) |
| AU (1) | AU2002351347A1 (ru) |
| CA (1) | CA2470114A1 (ru) |
| EA (2) | EA009795B1 (ru) |
| HR (1) | HRP20040535A2 (ru) |
| HU (1) | HUP0700116A2 (ru) |
| MX (1) | MXPA04005603A (ru) |
| NO (1) | NO20042902L (ru) |
| NZ (1) | NZ533935A (ru) |
| PL (1) | PL370061A1 (ru) |
| UA (1) | UA77990C2 (ru) |
| WO (1) | WO2003050085A1 (ru) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7411075B1 (en) | 2000-11-16 | 2008-08-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
| IL156055A0 (en) | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
| US7501450B2 (en) | 2000-11-30 | 2009-03-10 | Teva Pharaceutical Industries Ltd. | Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
| AU2003217653A1 (en) * | 2002-02-15 | 2003-09-09 | Teva Pharmaceutical Industries Ltd. | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation, as well as novel processes for preparing atorvastatin hemi-calcium forms i, viii and ix |
| US20050271717A1 (en) | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
| US7655692B2 (en) | 2003-06-12 | 2010-02-02 | Pfizer Inc. | Process for forming amorphous atorvastatin |
| ES2586561T3 (es) * | 2004-07-16 | 2016-10-17 | Lek Pharmaceuticals D.D. | Productos de degradación oxidativa de atorvastatina calcio |
| MX2007000765A (es) | 2004-07-20 | 2007-03-28 | Warner Lambert Co | Formas cristalinas de sal de calcio del acido (r-(r*, r*))-2- (4-fluorofenil)- beta,gama- dihidroxi-5- (1-metiletil)-3 -fenil-4-((fenilamino) (carbonil)-1ih -pirrol-1- heptanoico (2:1). |
| MX2007004722A (es) | 2004-10-28 | 2007-06-15 | Warner Lambert Co | Procedimiento para formar atorvastatina amorfa. |
| WO2006048894A1 (en) * | 2004-11-05 | 2006-05-11 | Morepen Laboratories Limited | Novel crystalline forms of atorvastatin calcium and processes for preparing them. |
| CA2547216A1 (en) | 2005-09-21 | 2007-03-21 | Renuka D. Reddy | Process for annealing amorphous atorvastatin |
| PT1957452E (pt) | 2005-11-21 | 2010-05-25 | Warner Lambert Co | Novas formas de ácido [r-(r*,r*)]-2-(4-fluorofenil)-b,b--di-hidroxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)-carbonil]-1h-pirrole-1-heptanóico magnésico |
| US8080672B2 (en) * | 2005-12-13 | 2011-12-20 | Teva Pharmaceutical Industries Ltd. | Crystal form of atorvastatin hemi-calcium and processes for preparation thereof |
| KR20120011249A (ko) | 2010-07-28 | 2012-02-07 | 주식회사 경보제약 | 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법 |
| US9328101B2 (en) * | 2012-05-25 | 2016-05-03 | Basf Se | Crystalline form B of 1,5-dimethyl-6-thioxo-3-(2,2,7-trifluoro-3-oxo-4-(prop-2-ynyl)-3,4-dihydro-2H-benzo[B][1,4]oxazin-6-yl)-1,3,5-triazinane-2,4-dione |
| CN104945300B (zh) * | 2015-06-17 | 2017-05-10 | 北京嘉林药业股份有限公司 | 一种ⅰ型阿托伐他汀钙的纯化方法 |
| CN104983702A (zh) * | 2015-07-23 | 2015-10-21 | 青岛蓝盛洋医药生物科技有限责任公司 | 一种治疗高胆固醇血症的药物阿托伐他汀钙组合物片剂 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4681893A (en) * | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
| US5149837A (en) * | 1988-02-22 | 1992-09-22 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| US5097045A (en) * | 1989-02-01 | 1992-03-17 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| US5003080A (en) * | 1988-02-22 | 1991-03-26 | Warner-Lambert Company | Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis |
| US5245047A (en) * | 1988-02-22 | 1993-09-14 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| US5124482A (en) * | 1988-02-22 | 1992-06-23 | Warner-Lambert Company | Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis |
| US5216174A (en) * | 1988-02-22 | 1993-06-01 | Warner-Lambert Co. | Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| US5248793A (en) * | 1990-10-17 | 1993-09-28 | Warner-Lambert Company | Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
| US5103024A (en) * | 1990-10-17 | 1992-04-07 | Warner-Lambert Company | Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
| US5155251A (en) * | 1991-10-11 | 1992-10-13 | Warner-Lambert Company | Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate |
| US5298627A (en) * | 1993-03-03 | 1994-03-29 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| HRP960313B1 (en) * | 1995-07-17 | 2002-08-31 | Warner Lambert Co | Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1) |
| HRP960312B1 (en) * | 1995-07-17 | 2001-10-31 | Warner Lambert Co | NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1) |
| ES2167587T3 (es) * | 1995-07-17 | 2002-05-16 | Warner Lambert Co | Forma cristalina de la sal hemicalcica del acido (r-(r*,r*))-2-(4-fluorofenil)-beta,delta-dihidroxi-5-(1-metiletil)-3-fenil-4-((fenilamino)carbonil)-1h-pirrol-1-heptanoico (atorvastatina). |
| US6087511A (en) * | 1996-07-16 | 2000-07-11 | Warner-Lambert Company | Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1) |
| IN191236B (ru) * | 1999-05-25 | 2003-10-11 | Ranbaxy Lab Ltd | |
| JP2003514798A (ja) * | 1999-11-17 | 2003-04-22 | テバ ファーマシューティカル インダストリーズ リミティド | アトルバスタチンカルシウムの多形 |
| CA2431068C (en) * | 2000-12-27 | 2008-06-10 | Ciba Specialty Chemicals Holding Inc. | Crystalline forms of atorvastatin |
-
2002
- 2002-11-12 UA UA20040604498A patent/UA77990C2/uk unknown
- 2002-12-11 HU HU0700116A patent/HUP0700116A2/hu unknown
- 2002-12-11 CN CNA2008101750211A patent/CN101565394A/zh active Pending
- 2002-12-11 CA CA002470114A patent/CA2470114A1/en not_active Abandoned
- 2002-12-11 US US10/316,822 patent/US20050209306A1/en not_active Abandoned
- 2002-12-11 NZ NZ533935A patent/NZ533935A/xx unknown
- 2002-12-11 EA EA200700331A patent/EA009795B1/ru not_active IP Right Cessation
- 2002-12-11 PL PL02370061A patent/PL370061A1/xx unknown
- 2002-12-11 CN CNA028269519A patent/CN1612859A/zh active Pending
- 2002-12-11 JP JP2003551110A patent/JP2005516008A/ja active Pending
- 2002-12-11 MX MXPA04005603A patent/MXPA04005603A/es active IP Right Grant
- 2002-12-11 KR KR10-2004-7009103A patent/KR20040091612A/ko not_active Application Discontinuation
- 2002-12-11 EP EP02787001A patent/EP1472220A4/en not_active Withdrawn
- 2002-12-11 WO PCT/US2002/039512 patent/WO2003050085A1/en active Application Filing
- 2002-12-11 AU AU2002351347A patent/AU2002351347A1/en not_active Abandoned
- 2002-12-11 EA EA200400789A patent/EA008441B1/ru not_active IP Right Cessation
-
2004
- 2004-06-11 HR HR20040535A patent/HRP20040535A2/hr not_active Application Discontinuation
- 2004-07-09 NO NO20042902A patent/NO20042902L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN1612859A (zh) | 2005-05-04 |
| EA009795B1 (ru) | 2008-04-28 |
| WO2003050085A8 (en) | 2004-11-11 |
| EA008441B1 (ru) | 2007-06-29 |
| JP2005516008A (ja) | 2005-06-02 |
| EA200400789A1 (ru) | 2004-12-30 |
| EP1472220A4 (en) | 2005-06-01 |
| EA200700331A1 (ru) | 2007-06-29 |
| US20050209306A1 (en) | 2005-09-22 |
| EP1472220A1 (en) | 2004-11-03 |
| MXPA04005603A (es) | 2005-10-18 |
| WO2003050085A1 (en) | 2003-06-19 |
| PL370061A1 (en) | 2005-05-16 |
| NZ533935A (en) | 2006-03-31 |
| CN101565394A (zh) | 2009-10-28 |
| HUP0700116A2 (en) | 2007-05-29 |
| AU2002351347A1 (en) | 2003-06-23 |
| KR20040091612A (ko) | 2004-10-28 |
| CA2470114A1 (en) | 2003-06-19 |
| UA77990C2 (en) | 2007-02-15 |
| HRP20040535A2 (en) | 2005-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20042902L (no) | Krystallinsk atorvastatinkalsium pa form Je, fremgangsmater for fremstilling derav, et farmasoytisk preparat omfattende denne samt dens anvendelse | |
| IL180112A0 (en) | Condensed benzamide compounds and pharmaceutical compositions containing the same | |
| NO20033143L (no) | Farmasoytisk preparat | |
| IL165977A (en) | Substituted pyrimidinylaminobenzamides , process for the preparation thereof and pharmaceutical compositions comprising the same | |
| NO20030418L (no) | Nytt farmasöytisk preparat | |
| ATE495731T1 (de) | Amphetaminsalz-formulierung mit verzögerter wirkstofffreigabe | |
| AU2003291103A8 (en) | Pharmaceutical composition | |
| TWI319318B (en) | Modified release pharmaceutical formulation | |
| NO20051956D0 (no) | Salmeterol superfin formulering | |
| DK1467724T3 (da) | Farmaceutisk sammensætning med agomelatin til dispergering i mundhulen | |
| EP1425019A4 (en) | PHARMACEUTICAL COMPOSITION | |
| IL172814A0 (en) | Novel solid pharmaceutical composition comprising amisulpride | |
| IL154370A0 (en) | Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same | |
| PL394600A1 (pl) | Związek winyloazacykloalkanowy, sposób jego wytwarzania i jego zastosowanie oraz kompozycja farmaceutyczna | |
| HUP0303948A2 (hu) | Szájban diszpergálódó szilárd gyógyszerforma | |
| DE60305728D1 (de) | PHARMAZEUTISCHE ZUSAMMENSETZUNG MIT VERLuNGERTER FREISETZUNG | |
| IL150910A0 (en) | Agrochemical composition containing phosphite and process for the preparation thereof | |
| NO20025805L (no) | Farmasöytisk preparat | |
| GB0316206D0 (en) | Pharmaceutical formulation | |
| DE60217390D1 (de) | Bicalutamid enthaltende pharmazeutische zusammensetzung | |
| GB0305679D0 (en) | Agrochemical formulation | |
| DE10291905D2 (de) | Pharmazeutische Zusammensetzung | |
| IL150907A0 (en) | Stable amorphous calcium pseudomonate and process for the preparation thereof | |
| AU2003229181A1 (en) | Stable dosage forms comprising atorvastatin calcium | |
| DE10107261B4 (de) | Pharmazeutische Zusammensetzung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |